RNLX
Closed
Renalytix Ai
0.1407
-0.0015 (-1.05%)
Last Update: 06 Dec 2024 17:30:00
Yesterday: 0.1422
Day's Range: 0.1407 - 0.16
Send
sign up or login to leave a comment!
When Written:
2.43
Renalytix AI is a leading developer of artificial intelligence-enabled clinical diagnostics for kidney disease. The company was founded in 2018 and is headquartered in New York City. Renalytix AI's mission is to improve kidney disease detection, management, and treatment through the use of advanced machine learning algorithms and data analytics.
The company's flagship product is KidneyIntelX, a diagnostic platform that uses a combination of blood-based biomarkers, clinical data, and machine learning algorithms to identify patients at high risk of developing kidney disease. KidneyIntelX is designed to help healthcare providers make more accurate and timely diagnoses, and to enable earlier interventions to slow or prevent the progression of kidney disease.
Renalytix AI has partnerships with leading healthcare providers and research institutions around the world, including Mount Sinai Health System, the University of Utah, and the National Kidney Foundation. The company is also a member of the Kidney Health Initiative, a public-private partnership between the US Food and Drug Administration and the American Society of Nephrology.
Renalytix AI is a publicly traded company, listed on the NASDAQ under the ticker symbol RNLX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's flagship product is KidneyIntelX, a diagnostic platform that uses a combination of blood-based biomarkers, clinical data, and machine learning algorithms to identify patients at high risk of developing kidney disease. KidneyIntelX is designed to help healthcare providers make more accurate and timely diagnoses, and to enable earlier interventions to slow or prevent the progression of kidney disease.
Renalytix AI has partnerships with leading healthcare providers and research institutions around the world, including Mount Sinai Health System, the University of Utah, and the National Kidney Foundation. The company is also a member of the Kidney Health Initiative, a public-private partnership between the US Food and Drug Administration and the American Society of Nephrology.
Renalytix AI is a publicly traded company, listed on the NASDAQ under the ticker symbol RNLX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!